| G1 N = 64 | G2 N = 136 | G3 N = 201 | P value |
Surgery of the primary tumor, n (%) | 42 (66) | 94 (69) | 171 (85) | <0.001 |
Surgery of liver metastases, n (%) | 9 (14) | 24 (17.5) | 40 (19.6) | 0.3 |
First line chemotherapy, n (%) |
|
|
|
|
Capecitabine | - | - | 26 (12.8) | <0.001 |
Fufol | 49 (76) | - | - |
|
LV5FU2 | 8 (13) | 16 (12) | 11 (5) |
|
Folfiri | - | 113 (83) | 101 (50.3) |
|
Folfox | - | 7 (5) | 60 (29.6) |
|
Folfirinox | - | - | 1 (0.6) |
|
Bevacizumab-Folfiri | - | - | 2 (1.1) |
|
Evaluation after 3 cycles, n (%) |
|
|
|
|
OR | 21 (33) | 68 (50) | 116 (57.8) | 0.01 |
CR | 5 (8) | 16 (11.5) | 46 (23.1) | 0.001 |
Evaluation after 6 cycles, n (%) |
|
|
|
|
OR | 22 (35) | 68 (50) | 105 (52.1) | 0.049 |
CR | 6 (9) | 38 (28) | 21 (10.1) | <0.001 |
Second line chemotherapy, n (%) | 17 (26.6) | 39 (28.7) | 79 (39.3) |
|
Capecitabine | - | 5 (14) | 18 (22.8) | 0.02 |
LV5FU2 | 2 (12) | - | 2 (2.5) |
|
Folfiri | - | - | 29 (36.7) |
|
Folfox | - | 18 (46) | 27 (34.2) |
|
Bevacizumab-Folfiri | - | - | 2 (2.5) |
|
Evaluation after 6 cycles, n (%) OR | - | - | 36 (45.5) |
|
Third line chemotherapy, n (%) | 3 (4.7) | 5 (3.7) | 30 (14.9) | <0.001 |
Capecitabine | - | - | 18 (60) |
|
Folfiri | - | - | 5 (16.7) |
|
Folfox | - | - | 4 (13.3) |
|
Bevacizumab-Folfiri | - | - | 1 (3.3) |
|
Others | - | - | 2 (0.6) |
|
Evaluation after 6 cycles, n (%) |
|
|
|
|
OR | - | - | 7 (22.2) |
|